Abstracts tagged "Comorbidity"

Abstract Number: 0883 • ACR Convergence 2021
Multimorbidity Burden in Systemic Lupus Erythematosus: A Nationwide Study
Ali Duarte-Garcia¹, Herbert Heien¹, Nilay Shah¹ and Cynthia Crowson², ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Eyota, MN
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have an increased risk of osteoporosis, end-stage renal disease, cardiovascular disease, and other comorbidities. The presence of multiple…
Abstract Number: 1663 • ACR Convergence 2021
The Influence of Comorbidity on Mortality in Patients with Rheumatoid Arthritis 1980-2015: A Longitudinal Population-based Study in Western Australia
Khalid Almutairi¹, Johannes Nossent¹, David Preen¹, Helen Keen² and Charles Inderjeeth³, ¹University of Western Australia, Perth, Australia, ²University of Western Australia, Daglish, Australia, ³University of Western Australia, Nedlands, Perth, Australia
Background/Purpose: Rheumatoid arthritis (RA) contributes to excess morbidity and mortality in RA patients compared with the general population. In Australia, there is a paucity of…
Abstract Number: 0093 • ACR Convergence 2021
The Association of General and Covid-19-Specific Stress with Changes in Patient-Reported Outcomes and Comorbidities
Patricia Katz¹, Kristin Wipfler², Sofia Pedro³ and Kaleb Michaud⁴, ¹University of California San Francisco, San Francisco, CA, ²FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ³Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ⁴University of Nebraska Medical Center, Omaha, NE
Background/Purpose: We previously showed that perceived stress during the COVID-19 pandemic was associated with concomitant increases in symptoms of depression and anxiety. In lupus alone,…
Abstract Number: 1031 • ACR Convergence 2021
Clinical and Humanistic Burden of Dermatomyositis and Polymyositis in the United States: A Systematic Literature Review
Swamy Venuturupalli¹, Namita Goyal², Nathalie Fortune³, Richard Leff⁴, Konrad Pisarczyk⁵, Izabela Aleksanderek⁶, Kiruthi Palaniswamy⁷ and Noreen Henig⁸, ¹Cedars-Sinai Medical Center, Beverly Hills, CA, ²University of California Irvine, Irvine, CA, ³Attune Health, Beverly Hills, CA, ⁴Richard L Leff MD LLC, Chadds Ford, PA, ⁵Maple Health Group, Krakow, Poland, ⁶Maple Health Group, Toronto, ON, Canada, ⁷Kezar Life Sciences, Los Angeles, CA, ⁸Kezar Life Sciences, Inc, Foster City, CA
Background/Purpose: Dermatomyositis (DM) and polymyositis (PM) are rare heterogenous systemic autoimmune disorders of the skin, muscles, and other organs that may have a devastating impact…
Abstract Number: 1670 • ACR Convergence 2021
Increased Prevalence of Gastroesophageal Disease Among Patients with Rheumatoid Arthritis: A Systematic Review and Meta-analysis
Patompong Ungprasert¹, Nipith Charoenngam², Ben Ponvilawan³, Pitchaporn Yingchoncharoen³ and Jerapas Thongpiya⁴, ¹Cleveland Clinic, Cleveland Heights, OH, ²Mount Auburn Hospital, Boston, MA, ³Mahidol University, Bangkok, Thailand, ⁴Mahdiol University, Bangkok, Thailand
Background/Purpose: Recent experimental studies have suggested that systemic inflammatory response could lead to impairment of lower esophageal function, resulting in gastroesophageal reflux disease (GERD). Epidemiologic…
Abstract Number: 0134 • ACR Convergence 2021
Systemic Lupus Erythematosus Is a Risk Factor for Mortality in Older Patients with Early-Stage Breast Cancer
Sebastian Bruera¹, Xiudong Lei², Xerxes Pundole², Hui Zhao², Sharon Giordano², Surabhi Vinod¹ and Maria Suarez-Almazor², ¹Baylor College of Medicine, Houston, TX, ²University of Texas MD Anderson Cancer Center, Houston, TX
Background/Purpose: Women with systemic lupus erythematosus (SLE) who develop breast cancer (BC), may receive different therapies (e.g. radiation) than women with BC who do not…
Abstract Number: 1033 • ACR Convergence 2021
Physical Inactivity Among Adults with Specific Chronic Conditions, by Arthritis Status, 49 States and District of Columbia, Behavioral Risk Factor Surveillance System, 2019
Dana Guglielmo¹, Charles Helmick², Michael Boring³, Kristina Theis², Louise Murphy⁴, Kathleen Watson², Lisa McGuire² and Lindsey Duca⁵, ¹Student, Atlanta, GA, ²Centers for Disease Control and Prevention, Atlanta, GA, ³ASRT Inc., Atlanta, GA, ⁴Optum Life Sciences, Inc., Eden Prairie, MN, ⁵Centers for Disease Control, Atlanta, GA
Background/Purpose: Arthritis is associated with reduced physical activity (PA). PA can improve functional status, brain health, and weight management, reduce pain, prevent chronic disease, falls,…
Abstract Number: 1780 • ACR Convergence 2021
Racial Disparities in Comorbidities of Patients with Psoriatic Arthritis
Sabahath Jaleel¹, Yael Ross¹ and Marina Magrey², ¹Case Western Reserve University at MetroHealth Medical Center, Cleveland, OH, ²Case Western Reserve Universtiy at MetroHealth Medical Center, Cleveland, OH
Background/Purpose: Racial heterogeneity of the US population makes it imperative to study the racial differences in clinical characteristics, medication use and co-morbidities of PsA patients…
Abstract Number: 0235 • ACR Convergence 2021
Are Comorbidities in Patients with Chronic Inflammatory Rheumatic Diseases Associated with Treatment Adherence to Biosimilars in a Non-medical Switch Scenario?
Imke Redeker¹, Stefan Moustakis², Styliani Tsiami², Xenofon Baraliakos², Ioana Andreica², Bjoern Buehring², Juergen Braun² and Uta Kiltz², ¹German Rheumatism Research Centre (DRFZ), Berlin, Germany, ²Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany
Background/Purpose: The availability of biosimilars has created a financial incentive to encourage non-medical switching if cheaper products are on the market. In patients with chronic…
Abstract Number: 1049 • ACR Convergence 2021
Multimorbidity Differences Between Systemic Lupus Erythematosus Patients and Comparators in Different Age Groups: A Large Nationwide US Study
Ali Duarte-Garcia¹, Herbert Heien¹, Nilay Shah¹ and Cynthia Crowson², ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Eyota, MN
Background/Purpose: Patients with Systemic Lupus Erythematosus (SLE) have an increased burden of multimorbidity. Age is strongly associated with accumulation of comorbidities. Patients with SLE may…
Abstract Number: 1844 • ACR Convergence 2021
Efficacy and Safety of Nintedanib in Patients with Systemic Sclerosis-Associated ILD (SSc-ILD) and Differing Comorbidity Burden: Subgroup Analyses of the SENSCIS Trial
Kristin B Highland¹, Teng Moua², Martin Aringer³, Takashi Ogura⁴, Corinna Miede⁵, Margarida Alves⁶ and Virginia Steen⁷, ¹Cleveland Clinic, Cleveland, OH, ²Division of Pulmonary and Critical Care Medicine, Mayo Clinic Rochester, Rochester, MN, ³Rheumatology, Medicine III, University Medical Center & Faculty of Medicine, TU Dresden, Dresden, Germany, ⁴Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Centre, Yokohama, Japan, ⁵mainanalytics GmbH, Sulzbach (Taunus), Germany, Sulzbach, Germany, ⁶Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim, Germany, ⁷Division of Rheumatology, Georgetown University, Washington, DC
Background/Purpose: In the SENSCIS trial in patients with SSc-ILD, nintedanib reduced the rate of decline in forced vital capacity (FVC) vs placebo. Patients with SSc-ILD…
Abstract Number: 0354 • ACR Convergence 2021
A Cross-Sectional Study of Rheumatoid Arthritis Diagnoses in Patients with Systemic Lupus Erythematosus
Kathryn Starzyk¹, Gary Curhan² and Julia Brault², ¹OM1, Inc, Boston, MA, ²OM1, Boston, MA
Background/Purpose: Features of autoimmune conditions may coexist in individual patients, which may represent an overlapping single disease with features of both (i.e., ‘rhupus’), or the…
Abstract Number: 1102 • ACR Convergence 2021
Comorbidities and Causes of Hospitalizations in a Cohort of IgG4-Related Disease Patients from a Single Center
David Faz-Muñoz, Eduardo Martin-Nares, Alejandra Hernández-Delgado and Gabriela Hernandez-Molina, Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: The frequency and types of comorbidities, causes of hospitalization, and the differences among clinical phenotypes in patients with IgG4-related disease (IgG4-RD) have not been…
Abstract Number: 1924 • ACR Convergence 2021
Patient Clustering Based on Multimorbidity Patterns Predicts Healthcare Utilization and Mortality in Rheumatoid Arthritis Within Independent Real-World Datasets
Bryant England¹, Yangyuna Yang¹, Punyasha Roul¹, Christian Haas², Harlan Sayles¹, Fang Yu¹, Brian Sauer³, Joshua Baker⁴, Kaleb Michaud¹, Jeffrey Curtis⁵ and Ted Mikuls¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Nebraska Omaha, Omaha, NE, ³University of Utah, Salt Lake City, UT, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Rheumatoid arthritis (RA) leads to substantial healthcare utilization and premature mortality. Prior work has demonstrated that the overlapping presence of comorbid chronic conditions, termed…
Abstract Number: 0491 • ACR Convergence 2020
Relationship Between Rheumatoid Arthritis and Pulmonary Function in the UK Biobank
Lauren C. Prisco¹, Matthew Moll¹, Jiaqi Wang², Weixing Huang³, Lily Martin¹, Vanessa Kronzer⁴, Sicong Huang², Edwin Silverman², Tracy J. Doyle⁵, Michael Cho⁵ and Jeffrey Sparks⁶, ¹Brigham and Women's Hospital, Boston, ²Brigham and Women's Hospital, Boston, MA, ³Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, ⁴Mayo Clinic, Rochester, MN, ⁵Brigham and Women's Hospital, West Roxbury, MA, ⁶Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Established pulmonary manifestations of RA include restrictive processes such as interstitial lung disease and obstructive processes such as bronchiectasis, but clinically detected forms of…

« Previous Page
1
…
8
9
10
11
12
…
19
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].